The global uveitis treatment market is expected to exhibit a strong 5.6% CAGR over the forecast period from 2019 to 2025, according to the latest research report from Market Research Future (MRFR). The global uveitis treatment market is expected to be valued at USD 764.5 million by 2025, according to the report.
Uveitis is an eye conditions, an inflammation of the middle layer of the eyeball, called the uvea. Uveitis is manifested through symptoms such as redness of the eye, pain, and blurred vision. These are the prime symptoms of uveitis. The disease usually occurs in people aged 20 to 50 and can cause significant distress due to the pain and blurry vision caused by the problem. The growing prevalence of uveitis is the major driver for the global uveitis treatment market growth over the forecast period from 2019 to 2025.
The growing prevalence of uveitis is due to the increasing threat of air pollution, which is a major causative factor for the inflammation of delicate body parts such as the inner regions of the eye. This is likely to remain a major driver for the uveitis treatment market over the forecast period, as growing urbanization around the world is likely to intensify the problem of air pollution in the coming years.
Get Sample Copy of Report @ https://www.marketresearchfuture.com/sample_request/8457
Increasing expenditure on R&D to find solutions for uveitis is likely to be a major driver for the global uveitis treatment market. The increasing awareness about uveitis among the general populace is the key driver for this phenomenon, as this has driven the demand for effective cures for the condition. Increasing product launches in the uveitis treatment market are also likely to remain a major driver for the market over the forecast period. On the other hand, the widespread use of corticosteroid drugs is likely to be the major restraint on the market, as there are various side effects of corticosteroid drugs that patients want to avoid.
Competitive Dynamics
Novartis AG (Switzerland), Allergan PLC (Ireland), Bausch Health (Canada), AbbVie Inc. (US), EyePoint Pharmaceuticals, Inc. (US), Horizon Therapeutics Plc (Ireland), Alimera Sciences (US), and Mylan NV (US), are some of the major players operating in the uveitis treatment market.
Analytical Segmentation
The global market for uveitis therapy has been divided into three categories: type, drug class, and end-user.
The market has been classified into anterior uveitis, intermediate uveitis, posterior uveitis, and others based on the kind of uveitis. In the worldwide uveitis treatment market, anterior uveitis is expected to have the largest market share.
The global uveitis treatment market has been divided into corticosteroid medications, anti-inflammatory medications, immunosuppressive medications, and other drug classes depending on medication class. Because of the increased preference in the treatment of uveitis, the corticosteroids medicines category is expected to hold the greatest share of the market.
Hospitals, specialist clinics, and others are among the market's end-user segments. As these are the principal venues where patients receive treatment, the hospital sector is likely to hold the greatest share of the market.
Regional Overview
In 2018, the Americas had the largest regional market. The United States has about 7,200 operating hospitals and a thriving healthcare industry. This helps to fuel growth in the region's uveitis treatment industry. Because of the increased prevalence of noninfectious uveitis in the United States, North America dominated the market. Furthermore, excellent healthcare facilities and attractive reimbursement rules are credited with driving regional development. In the United States, a great number of medications are commercially available, which is driving up demand. Furthermore, as the incidence of uveitis rises in the United States, the market is expected to expand. In the United States, the annual rate of uveitis ranges from 26.6 to 102 per 100,000 persons. Furthermore, uveitis is responsible for roughly 2.8 percent of blindness cases in the United States.
Due to the increased prevalence of uveitis in the European region, increased R&D initiatives, and rising healthcare expenditure in the region, there is a strong need for uveitis therapy in this region. A crucial aspect driving regional growth is the growing number of elderly people. Germany has experienced tremendous expansion as a result of an aging population and a high prevalence of eye illnesses.
Get Access Full Report @ https://www.marketresearchfuture.com/reports/uveitis-treatment-market-8457
The Asia-Pacific region is the uveitis treatment market's fastest-growing region. It is home to the world's greatest population and a burgeoning healthcare industry. Growing understanding of the numerous treatment options has also resulted in rapid regional expansion. The rising incidence of uveitis and related illnesses, the growing elderly population, and increased investments in research and development by drug manufacturing businesses for creating new treatments such as corticosteroids are all contributing to the regional market's growth.
Due to low per capita disposable incomes and limited development of healthcare facilities, MEA is expected to have the smallest proportion of the worldwide market.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York, New York 10013,
United States of America
+1 646 845 9312
